An Exploratory Phase I Study in Healthy Volunteers of GI Transit Following Administration of the ß3-Adrenergic Receptor Agonist, Solabegron (Study B3I106248).
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2009
At a glance
- Drugs Solabegron (Primary)
- Indications Irritable bowel syndrome; Overactive bladder
- Focus Pharmacodynamics
- 06 Apr 2009 New trial record